All In Biotech

Drug Trial Radar · NCT05696626

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Oct 31, 2023

Primary completion

Apr 2027

Study completion Apr 2028

Sponsor

Lead sponsor
LeonaBioIndustry
Sponsor type
Industry
First posted
Jan 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.

Conditions

  • Metastatic Breast Cancer

Interventions

  • Lasofoxifene in combination with abemaciclibDrug

    5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day

  • Fulvestrant in combination with abemaciclibDrug

    Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: Within approximately 3 years

Locations

224 sites in 17 countries. Site status is shown where the registry gives one.

  • Mayo Clinic - Scottsdale

    Scottsdale, Arizona · Recruiting

  • University of Arizona - Cancer Center

    Tucson, Arizona · Recruiting

  • Providence Medical Foundation - Santa Rosa, CA

    Santa Rosa, California · Recruiting

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida · Recruiting

  • Miami Cancer Institute

    Miami, Florida · Recruiting

  • Miami Cancer Institute Plantation

    Plantation, Florida · Recruiting

  • Emory University School of Medicine

    Atlanta, Georgia · Recruiting

  • Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • Johns Hopkins Kimmel Cancer Center

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Completed

  • Cancer and Hematology Centers of Western Michigan

    Grand Rapids, Michigan · Recruiting

  • Allina Health System DBA Virginia Piper Cancer Institute

    Minneapolis, Minnesota · Completed

  • Mayo Clinic - Rochester

    Rochester, Minnesota · Recruiting

  • Saint Luke's Cancer Institute

    Kansas City, Missouri · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Renown Regional Medical Centre

    Reno, Nevada · Recruiting

  • Cancer Care Specialists

    Reno, Nevada · Recruiting

  • New Jersey Cancer Care, PA

    Belleville, New Jersey · Withdrawn

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • Presbyterian Kaseman Hospital

    Albuquerque, New Mexico · Not yet recruiting

  • Presbyterian Rust Cancer Center

    Rio Rancho, New Mexico · Recruiting

  • The Blavatnik Family - Chelsea Medical Center at Mount Sinai

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Altru Health Systems

    Grand Forks, North Dakota · Completed

  • University Hospitals Seidman Cancer Center

    Cleveland, Ohio · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Withdrawn

  • The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James)

    Columbus, Ohio · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Completed

  • Baylor College of Medicine

    Houston, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Harris Health System - Smith Clinic

    Houston, Texas · Recruiting

  • Swedish Cancer Institute (SCI)

    Seattle, Washington · Withdrawn

  • Blacktown Hospital

    Blacktown, Australia · Recruiting

  • Concord Repatriation General Hospital

    Concord, Australia · Recruiting

  • Mater Misericordiae Ltd, South Brisbane

    South Brisbane, Australia · Recruiting

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium · Recruiting

Showing 40 of 224 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.